Subscribe To
VKTX / Viking Therapeutics' stock rallies after Madrigal shares positive data about its liver drug
VKTX News
By The Motley Fool
November 4, 2023
1 Under-the-Radar Stock That Could Triple By 2030
Viking Therapeutics is looking to profit from the expanding market for obesity drugs. The company's two leading candidates are currently in phase 2 cl more_horizontal
By InvestorPlace
October 18, 2023
Why Is Viking Therapeutics (VKTX) Stock Moving Today?
Viking Therapeutics (NASDAQ: VKTX ) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. more_horizontal
By Proactive Investors
October 18, 2023
Viking Therapeutics joins weight loss drug bandwagon as trial data impresses
Viking Therapeutics (NASDAQ:VKTX) shares shot up 12% in overnight US trading as the drug developer revealed more impressive trial data from a treatmen more_horizontal
By Market Watch
October 17, 2023
Viking Therapeutics' stock rallies following early drug study data
Viking Therapeutics Inc. VKTX, -0.37% shares rose in the extended session Tuesday after the biotech drug developer said data from an early stage clini more_horizontal
By The Motley Fool
June 27, 2023
Why Viking Therapeutics Is Plunging Today
After positive mid-stage data, Eli Lilly seems to have a chance at achieving best-in-class status in the valuable weight loss market. Viking's shares more_horizontal
By The Motley Fool
June 26, 2023
Why Viking Therapeutics Stock Is Crashing Today
A top competitor announced plans to move forward with a late-stage weight loss candidate today. Viking's weight-loss candidate is several years behind more_horizontal
By The Motley Fool
June 17, 2023
Could Viking Therapeutics Stock Help You Become a Millionaire?
Viking Therapeutics has a few drugs that have the potential to generate billions in revenue. The problem is that they are in early-stage trials, so th more_horizontal
By The Motley Fool
June 8, 2023
This Red-Hot Growth Stock Has Soared 885% in Just 12 Months
Viking Therapeutics is a biotech with multiple potential blockbuster drugs in its portfolio. Encouraging trial results have made investors bullish abo more_horizontal